A Big Deal: Strategic Rejuvenation for Post-Pandemic Realities

As we are emerging from the COVID-19 pandemic, the biopharmaceutical industry must adapt to new realities created by the disruption of legacy business models. Mergers and acquisitions (M&A) will play an important role in bringing about the necessary strategic rejuvenation of biopharmaceutical companies. However, pure M&A alone, in which assets or companies change ownership, is not the answer to all of the industry's challenges. Therefore, companies will need to judiciously embrace the full spectrum of deal-making options, including M&A and partnerships, to thrive in the post-pandemic world.